Head-To-Head Comparison: GSK (NYSE:GSK) & PainReform (NASDAQ:PRFX)
by Renee Jackson · The Cerbat GemGSK (NYSE:GSK – Get Free Report) and PainReform (NASDAQ:PRFX – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.
Valuation & Earnings
This table compares GSK and PainReform”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GSK | $43.07 billion | 2.36 | $7.54 billion | $3.20 | 15.67 |
| PainReform | $20,000.00 | 44.37 | -$5.02 million | ($736.66) | -0.00 |
GSK has higher revenue and earnings than PainReform. PainReform is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares GSK and PainReform’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GSK | 14.56% | 43.23% | 11.60% |
| PainReform | N/A | N/A | N/A |
Analyst Ratings
This is a summary of recent ratings and recommmendations for GSK and PainReform, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GSK | 2 | 7 | 1 | 1 | 2.09 |
| PainReform | 1 | 0 | 0 | 0 | 1.00 |
GSK currently has a consensus price target of $56.50, indicating a potential upside of 12.66%. Given GSK’s stronger consensus rating and higher possible upside, equities analysts plainly believe GSK is more favorable than PainReform.
Insider & Institutional Ownership
15.7% of GSK shares are owned by institutional investors. Comparatively, 37.3% of PainReform shares are owned by institutional investors. 10.0% of GSK shares are owned by company insiders. Comparatively, 34.4% of PainReform shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility and Risk
GSK has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, PainReform has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500.
Summary
GSK beats PainReform on 11 of the 15 factors compared between the two stocks.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
About PainReform
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.